Lipigon Pharmaceuticals AB (9RP) Stock Statistics & Valuation Metrics

Lipigon Pharmaceuticals AB has a market cap or net worth of €1.26M. The enterprise value is €26.87M.

Lipigon Pharmaceuticals AB has 126,422,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lipigon Pharmaceuticals AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Lipigon Pharmaceuticals AB is -2.28. Lipigon Pharmaceuticals AB’s PEG ratio is 0.03.

In the last 12 months, Lipigon Pharmaceuticals AB had revenue of 16.41M and earned -12.13M in profits. Earnings per share was -0.19.

In the last 12 months, operating cash flow was -32.33M and capital expenditures -235.00K, giving a free cash flow of -32.56M billion.

Lipigon Pharmaceuticals AB pays an annual dividend of ―, resulting in a dividend yield of ―

Lipigon Pharmaceuticals AB upcoming earnings date is May 27, 2025, TBA Not Confirmed.

Lipigon Pharmaceuticals AB as a current ratio of 6.51, with Debt / Equity ratio of 0.00%

In the past 12 months, Lipigon Pharmaceuticals AB has paid 0.00 in taxes.

Lipigon Pharmaceuticals AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Lipigon Pharmaceuticals AB has €10.74M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€10.74M billion.

Gross margin is 15.38%, with operating margin of -75.40%, and net profit margin of -73.92%.

The average price target for Lipigon Pharmaceuticals AB is ―, which is 11.43% higher than the current price. The consensus rating is ―